GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM

The purpose of this study is to better define longitudinal genomic alterations in patients with glioblastoma (GBM), and to determine if plasma circulating tumor DNA (ctDNA) or cell free DNA (cfDNA) is associated with disease recurrence, survival, tumor characteristics, and/or peripheral immunosuppression.

Inclusion Criteria:Age ≥ 18 yearsPatients newly diagnosed with malignant glioma, IDH wildtype who have undergone surgical resection for their tumor and who are planned for standard of care radiation therapy with concurrent temozolomide (i.e., at least 59 Gy in 30 fractions over 6 weeks)Patients must have leftover tissue available from the surgical resection of their tumor available to request for this research.Able to undergo MRI of brain with and without contrastSigned informed consent approved by the Institutional Review Board (IRB)Exclusion Criteria:Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin